Form 8-K

8-K — TACTILE SYSTEMS TECHNOLOGY INC

Accession: 0001104659-26-082947

Filed: 2026-07-13

Period: 2026-07-13

CIK: 0001027838

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — tm2620304d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2620304d1_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2620304d1_8k.htm · Sequence: 1

false

0001027838

TACTILE SYSTEMS TECHNOLOGY INC

0001027838

2026-07-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

July 13, 2026

TACTILE

SYSTEMS TECHNOLOGY, INC.

(Exact name

of registrant as specified in its charter)

Delaware

001-37799

41-1801204

(State

or other jurisdiction of

(Commission

(I.R.S.

Employer

incorporation)

File

Number)

Identification

No.)

3701

Wayzata Blvd, Suite 300,

Minneapolis, MN

55416

(Address of principal executive offices) (Zip

Code)

(612)

355-5100

(Registrant’s telephone number, including

area code)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered

pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which

registered

Common

Stock, Par Value $0.001 Per Share

TCMD

The

Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of

the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ¨

Emerging growth company

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation FD Disclosure.

On July 13, 2026, Tactile Systems Technology, Inc.

(“we,” “us,” and “our”) issued a press release announcing a distribution agreement. A copy of the

press release is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K,

the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18

of the Securities Exchange Act of 1934 or otherwise subject to the liability of that section, and shall not be incorporated by reference

into any registration statement or other document filed under the Securities Act of 1933 or the Securities Exchange Act of 1934, except

as shall be expressly set forth by specific reference in that filing.

Item 8.01. Other Events.

On July 13, 2026, we announced that we have

entered into an exclusive distribution agreement with ElastiMed, Inc. to bring MyoSleeve™, its discreet, wearable non-pneumatic

compression device for the lower leg, to Department of Veterans Affairs (“VA”) and Department of Defense (“DoD”)

patients across the United States. MyoSleeve expands our established market-leading portfolio by providing a new treatment option for

appropriately selected patients in earlier stages of chronic swelling who may not yet require more intensive compression therapy. MyoSleeve

may also be appropriate as a complementary treatment to a traditional pneumatic compression device and for patients who struggle with

conservative therapy, or those with mobility-limiting cases.

Wrapped around the calf with the ability to be

worn beneath clothing, MyoSleeve uses electroactive polymer technology to deliver dynamic compression through flexible bands that contract

in sequence. The battery-powered device is designed as an all-in-one therapy option, operating without tubing, cords, or an external controller,

and quietly delivers intermittent therapy while patients go about daily activities. MyoSleeve has received U.S. Food and Drug Administration

510(k) clearance and is indicated for the treatment of chronic swelling, including chronic edema, lymphedema, and venous insufficiency.

Under the agreement, we hold exclusive U.S. distribution

rights for MyoSleeve within the VA and DoD systems. In connection with these exclusive distribution rights, we made an upfront payment

of $3 million to ElastiMed. We also committed to certain minimum purchase obligations and marketing and sales promotion as we support

ElastiMed’s growth. We expect to leverage our established sales organization, billing and payment expertise, and patient support

infrastructure to drive MyoSleeve commercialization and support ongoing market access initiatives. MyoSleeve is available by prescription,

and appropriate patient selection is determined by the treating clinician.

Legal Notice Regarding Forward-Looking Statements

This report contains forward-looking statements,

including expectations regarding the distribution agreement and related actions. Forward-looking statements are generally identifiable

by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,”

“estimate,” “believe,” “intend,” “continue,” “confident,” “outlook,”

“guidance,” “project,” “goals,” “look forward,” “poised,” “designed,”

“plan,” “return,” “focused,” “prospects” or “remain” or the negative of these

words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking

statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements

untrue, including, but not limited to, our ability to obtain reimbursement from third-party payers for our products; adverse economic

conditions, including inflation, rising interest rates or a recession; the adequacy of our liquidity to pursue our business objectives;

price increases for supplies and components; wage and component price inflation; loss of a key supplier or other supply chain disruptions;

entry of new competitors and/or competitive products; compliance with and changes in federal, state and local government laws and regulations;

technological obsolescence of, or quality issues with, our products; our ability to expand our business through strategic acquisitions;

our ability to integrate acquisitions and related businesses; the effects of current and future U.S. and foreign trade policy and tariff

actions; or the inability to carry out research, development and commercialization plans. In addition, other factors that could cause

actual results to differ materially are discussed in our filings with the SEC. Investors and security holders are urged to read these

documents free of charge on the SEC’s website at http://www.sec.gov. We undertake no obligation to publicly update or revise our

forward-looking statements as a result of new information, future events or otherwise.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

EXHIBIT INDEX

Exhibit

No.

Description

99.1

Press Release dated July 13, 2026

104

Cover Page Interactive Data File (embedded within the

Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TACTILE SYSTEMS TECHNOLOGY, INC.

Date: July 13, 2026

By:

/s/ Elaine M. Birkemeyer

Elaine M. Birkemeyer

Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2620304d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Tactile Medical Enters Exclusive U.S. Distribution

Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients

Discreet, Battery-Powered Device Reaches Patients

at Earlier Stages of Disease Progression

MINNEAPOLIS, July 13, 2026 (GLOBE NEWSWIRE)

-- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology

company providing therapies for people with chronic disorders, today announced it has entered into an exclusive distribution agreement

with ElastiMed, Inc. to bring MyoSleeve™, its discreet, wearable non-pneumatic compression device for the lower leg, to Department

of Veterans Affairs (VA) and Department of Defense (DoD) patients across the United States. MyoSleeve expands Tactile Medical’s

established market-leading portfolio by providing a new treatment option for appropriately selected patients in earlier stages of chronic

swelling who may not yet require more intensive compression therapy. MyoSleeve may also be appropriate as a complementary treatment to

a traditional pneumatic compression device and for patients who struggle with conservative therapy, or those with mobility-limiting cases.

Wrapped around the calf with the ability to be worn beneath clothing,

MyoSleeve uses electroactive polymer technology to deliver dynamic compression through flexible bands that contract in sequence. The battery-powered

device is designed as an all-in-one therapy option, operating without tubing, cords, or an external controller, and quietly delivers intermittent

therapy while patients go about daily activities. MyoSleeve has received U.S. Food and Drug Administration 510(k) clearance and is

indicated for the treatment of chronic swelling, including chronic edema, lymphedema, and venous insufficiency.

Under the agreement, Tactile Medical holds exclusive U.S. distribution

rights for MyoSleeve within the VA and DoD systems. In connection with these exclusive distribution rights, the Company made an upfront

payment of $3 million to ElastiMed. The Company also committed to certain minimum purchase obligations and marketing and sales promotion

as it supports ElastiMed’s growth. The Company expects to leverage its established sales organization, billing and payment expertise,

and patient support infrastructure to drive MyoSleeve commercialization and support ongoing market access initiatives. MyoSleeve is available

by prescription, and appropriate patient selection is determined by the treating clinician.

“Our agreement with ElastiMed adds a differentiated, wearable

compression option to Tactile Medical’s portfolio and reflects our strategy of expanding access to patient-focused solutions across

the continuum of chronic swelling care,” said Sheri Dodd, Chief Executive Officer of Tactile Medical. “For the right patient,

MyoSleeve offers unobtrusive compression therapy that fits into daily life, giving patients the freedom to stay mobile while engaged in

their own care.”

"Partnering with Tactile Medical gives MyoSleeve a direct path

to certain patients with chronic swelling who want to stay active while getting the treatment they need,” said Omer Zelka, Chief

Executive Officer of ElastiMed. “It is the first ambulatory all-in-one, cable-free, clinical-grade solution for patients with venous

and lymphatic conditions. This partnership enables the first commercial introduction of MyoSleeve through a trusted and market-leading

medical device partner."

"Compression therapy is not one-size-fits-all. Clinicians achieve

the best outcomes when they have a range of options that can be matched to disease severity, anatomy, and lifestyle," said Tony

Gasparis, MD, Chief Medical Officer of Tactile Medical. "MyoSleeve introduces an important new option for appropriately selected

patients with lower-leg swelling, offering active compression that is well-suited for earlier stages of disease, where consistent therapy

adherence is key to slowing disease progression. Importantly, MyoSleeve is designed to complement — not replace — advanced

pneumatic compression therapies, which remain the standard of care for patients with more extensive or advanced disease."

For more information about MyoSleeve, please visit https://tactilemedical.com/myosleeve/.

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and

marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency

and chronic inflammatory lung disease by helping them live better and care for themselves. Tactile Medical collaborates with clinicians

to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life

for tens of thousands of patients each year.

About ElastiMed, Inc.

ElastiMed is a commercial-stage medical device

company developing wearable therapeutic devices based on electroactive polymer (EAP) technology, designed to deliver dynamic compression

in a comfortable, low-profile, and easy-to-use form.

Investor Inquiries:

Sam Bentzinger

Gilmartin Group

investorrelations@tactilemedical.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Jul. 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 13, 2026

Entity File Number

001-37799

Entity Registrant Name

TACTILE SYSTEMS TECHNOLOGY INC

Entity Central Index Key

0001027838

Entity Tax Identification Number

41-1801204

Entity Incorporation, State or Country Code

Entity Address, Address Line One

3701

Wayzata Blvd

Entity Address, Address Line Two

Suite 300

Entity Address, City or Town

Minneapolis

Entity Address, State or Province

Entity Address, Postal Zip Code

55416

City Area Code

612

Local Phone Number

355-5100

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, Par Value $0.001 Per Share

Trading Symbol

TCMD

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration